



wherein:

R_1 is selected from a member of the group consisting of hydrogen, hydroxyl, methoxyl, acylamino group, cyano group, sulfo, sulfinyl, sulfhydryl (mercapto), sulfeno, sulfanilyl, sulfamyl, sulfamino, and phosphino, phosphinyl, phospho, phosphono and $-NR_aR_b$, wherein each of R_a and R_b may be the same or different and each is selected from the group consisting of hydrogen and optionally substituted: $C_{(1-20)}$ alkyl, $C_{(3-12)}$ cycloalkyl, $C_{(2-20)}$ alkenyl, $C_{(3-12)}$ cycloalkenyl, $C_{(2-20)}$ alkynyl, aryl, heteroaryl, and heterocyclic group;

R_2 and R_3 are independently selected from a member of the group consisting of halo, oxo, $C_{(1-20)}$ alkyl, $C_{(1-20)}$ hydroxyalkyl, $C_{(1-20)}$ thioalkyl, $C_{(1-20)}$ alkylthio, $C_{(1-20)}$ alkylaminoalkyl, $C_{(1-20)}$ aminoalkyl, $C_{(1-20)}$ aminoalkoxyalkenyl, $C_{(1-20)}$ aminoalkoxyalkynyl, $C_{(1-20)}$ diaminoalkyl, $C_{(1-20)}$ triaminoalkyl, $C_{(2-20)}$ tetraaminoalkyl, $C_{(1-20)}$ alkylamido, $C_{(1-20)}$ alkylamidoalkyl, $C_{(1-20)}$ amidoalkyl, $C_{(1-20)}$ acetamidoalkyl, $C_{(2-20)}$ alkenyl, $C_{(2-20)}$ alkynyl, $C_{(1-20)}$ alkoxyl, $C_{(1-20)}$ alkoxyalkyl, $C_{(1-20)}$ dialkoxyalkyl, and $-NR_aR_b$; and

R_4 may be hydrogen or an optionally substituted member of the group consisting of $C_{(1-20)}$ alkyl, $C_{(3-12)}$ cycloalkyl, $C_{(2-20)}$ alkenyl, $C_{(3-12)}$ cycloalkenyl, $C_{(2-20)}$ alkynyl, aryl, heteroaryl, and heterocyclic group.

2. The therapeutic compound of claim 1, wherein R_2 and R_3 are independently selected from a member of the group consisting of hydrogen, halo, thio, oxo, $C_{(1-10)}$ alkyl, $C_{(1-10)}$ hydroxyalkyl, $C_{(1-10)}$ thioalkyl, $C_{(1-10)}$ alkylthio, $C_{(1-10)}$ alkylamino, $C_{(1-10)}$ alkylaminoalkyl, $C_{(1-10)}$ aminoalkyl, $C_{(1-10)}$ aminoalkoxyalkenyl, $C_{(1-10)}$ aminoalkoxyalkynyl, $C_{(1-10)}$ diaminoalkyl, $C_{(1-10)}$ triaminoalkyl, $C_{(2-10)}$ tetraaminoalkyl, $C_{(1-10)}$ aminotrialkoxyamino, $C_{(1-10)}$ alkylamido,